Co-Diagnostics taps warrant holders for cash as FDA clearance looms

Co-Diagnostics entered a warrant inducement agreement with existing warrant holders on July 30, 2026, convincing them to exercise warrants early in exchange for new warrants at revised terms. The post-IPO equity move brings in immediate cash without a traditional offering.

The timing tracks a regulatory bottleneck. Co-Diagnostics submitted its first 510(k) application for its Co-Dx PCR Pro instrument and a COVID-19 over-the-counter test in June 2024, and none of its tests carry FDA clearance yet.

The company is building out an infectious disease diagnostic platform. That FDA gap is the central variable deciding whether the platform becomes a commercial asset or stays a development-stage project.

Warrant inducement lets existing holders exercise early for new warrants on better terms, giving the company cash without a dilutive equity raise. The trade-off is downstream dilution when those new warrants convert.

The structure bets clearance arrives before the new warrants weigh on the stock. A rejection or extended review would leave Co-Diagnostics holding fresh warrant obligations against a balance sheet still unbacked by product sales.

The FDA's 510(k) decision on the Co-Dx PCR Pro is the one marker that matters. Clearance would validate the raise and open commercial revenue; anything else turns the financing into a liability.